Search results for "fibrosis"

showing 10 items of 901 documents

Prevalence and prognostic impact of nonischemic late gadolinium enhancement in stress cardiac magnetic resonance

2020

Aim To assess the prevalence and prognostic significance of NI-LGE in patients undergoing stress-CMR. Methods Stress-CMR with either dipyridamole or adenosine was performed in 283 patients (228 men, 81%) including perfusion imaging, wall motion evaluation and LGE. Follow-up was completed in all enrolled patients (median time: 1850 days; interquartile range: 1225-2705 days). Composite endpoint included cardiac death, ventricular tachycardia, myocardial infarction, stroke, hospitalization for cardiac cause and coronary revascularization performed beyond 90 days from stress-CMR scans. Results One hundred and twelve patients (40%) had negative LGE (no-LGE), 140 patients (49%) I-LGE and 31 patie…

MaleAdenosineTime FactorsVasodilator AgentsContrast MediaPerfusion scanning030204 cardiovascular system & hematologyVentricular tachycardia0302 clinical medicineRisk FactorsInterquartile rangePrevalence030212 general & internal medicineMyocardial infarctionStrokenonischemic fibrosislate gadolinium enhancement; nonischemic cardiac findings; nonischemic fibrosis; prognosis; stress perfusion cardiac magnetic resonanceDipyridamoleGeneral MedicineMiddle AgedMagnetic Resonance ImagingDipyridamolelate gadolinium enhancementstress perfusion cardiac magnetic resonanceembryonic structurescardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinePerfusionmedicine.drugnonischemic cardiac findingsmedicine.medical_specialtyHeart DiseasesPerfusion ImagingRisk Assessment03 medical and health sciencesPredictive Value of TestsInternal medicinemedicineHumanscardiovascular diseasesSurvival analysisAgedRetrospective Studiesbusiness.industryMyocardiummedicine.diseaseFibrosisLate gadolinium enhancement Nonischemic cardiac findings Nonischemic fibrosis Prognosis Stress perfusion cardiac magnetic resonanceprognosisbusinessJournal of Cardiovascular Medicine
researchProduct

Differential expression of PGC-1α and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts.

2011

11 pages, 6 figures. PMID:21687738[PubMed] PMCID: PMC3110204

MaleAgingMitochondrial DiseasesMitochondrial MyopathyUbiquinoneCardiomyopathylcsh:MedicineMitochondrionAMP-Activated Protein Kinasesp38 Mitogen-Activated Protein KinasesAntioxidantsAdenosine TriphosphateAMP-activated protein kinaseTrinucleotide RepeatsFibrosisMolecular Cell BiologyChildlcsh:ScienceHeat-Shock ProteinsRegulation of gene expressionMultidisciplinaryMovement DisordersbiologyNeuromuscular DiseasesMiddle AgedCatalasePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaCell biologyMitochondriaDNA-Binding ProteinsNeurologyDisease ProgressionMedicineFemalemedicine.symptomSignal TransductionResearch ArticleAdultcongenital hereditary and neonatal diseases and abnormalitiesAtaxiaAdolescentMitochondrial ProteinsmedicineGeneticsHumansBiologyAllelesGlutathione PeroxidaseSuperoxide Dismutaselcsh:RHuman GeneticsFibroblastsmedicine.diseaseMolecular biologyOxidative StressMitochondrial biogenesisGene Expression RegulationFriedreich Ataxiabiology.proteinFrataxinlcsh:QEnergy MetabolismReactive Oxygen SpeciesTranscription FactorsPLoS ONE
researchProduct

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching

2017

Introduction Current treatment with vasodilators for pulmonary hypertension associated with respiratory diseases is limited by their inhibitory effect on hypoxic pulmonary vasoconstriction (HPV) and uncoupling effects on ventilation-perfusion (V'/Q'). Hypoxia is also a well-known modulator of the nitric oxide (NO) pathway, and may therefore differentially affect the responses to phosphodiesterase 5 (PDE5) inhibitors and soluble guanylyl cyclase (sGC) stimulators. So far, the effects of the sGC stimulator riociguat on HPV have been poorly characterized. Materials and methods Contraction was recorded in pulmonary arteries (PA) in a wire myograph. Anesthetized rats were catheterized to record …

MaleAnoxemiaPulmonologyPulmonary FibrosisVasodilator Agentslcsh:MedicineVasodilation030204 cardiovascular system & hematologyPharmacologyVascular Medicinechemistry.chemical_compound0302 clinical medicineSoluble Guanylyl CyclaseHypoxic pulmonary vasoconstrictionPulmonary fibrosisMedicine and Health SciencesPulmonary Arterieslcsh:ScienceHypoxiaMultidisciplinaryVasodilatorsDrugsRespiratory organs diseasesArteriesMiddle AgedChemistryPhysical Sciencescardiovascular systemFemalemedicine.symptomAnatomyMedicamentsmedicine.drugResearch ArticleChemical Elementsinorganic chemicalsSildenafilHypertension PulmonaryChronic Obstructive Pulmonary DiseaseEnzyme ActivatorsIn Vitro TechniquesPulmonary ArteryRiociguatSildenafil CitrateMalalties de l'aparell respiratori03 medical and health sciencesMedical HypoxiamedicineVentilation-Perfusion RatioAnimalsHumansRats WistarAgedPharmacologybusiness.industrylcsh:RAnoxèmiaBiology and Life SciencesHypoxia (medical)Phosphodiesterase 5 Inhibitorsmedicine.diseasePulmonary hypertensionFibrosisRatsOxygenDisease Models AnimalPyrimidines030228 respiratory systemchemistryVasoconstrictionCardiovascular AnatomyPyrazolesBlood Vesselslcsh:QSoluble guanylyl cyclasebusinessDevelopmental Biology
researchProduct

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profil…

2011

Purpose Abnormal cytokine expression accompanies myelofibrosis and might be a therapeutic target for Janus-associated kinase (JAK) inhibitor drugs. This study describes the spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypic correlates and prognostic significance. Patients and Methods Patients included in this study were required to have archived plasma, bone marrow biopsy, and cytogenetic information available at the time of first referral to the Mayo Clinic. Multiplex biometric sandwich immunoassay was used to measure plasma levels of 30 cytokines. Results In total, 127 PMF patients were studied; comparison with normal controls (n = 35) r…

MaleCancer Researchmedicine.medical_treatmentBiopsyKaplan-Meier EstimateRisk FactorsMedicineMacrophage inflammatory proteinAged 80 and overInterleukin-15Janus kinase 2biologyInterleukinBone Marrow ExaminationMiddle AgedPrognosisInterleukin-12Up-RegulationCytokinePhenotypeOncologyInterleukin 15Cytogenetic AnalysisFemalemedicine.drugAdultGenotypeMinnesotaProtein Array AnalysisEnzyme-Linked Immunosorbent AssayRisk AssessmentPredictive Value of TestsBiomarkers TumorHumansMyelofibrosisInterferon alfaAgedProportional Hazards ModelsChi-Square Distributionbusiness.industryInterleukin-8Receptors Interleukin-2Janus Kinase 2medicine.diseasePacritinibPrimary MyelofibrosisCase-Control StudiesImmunologyMutationbiology.proteinbusinessJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

No evidence of adverse cardiac remodeling in former elite endurance athletes

2016

Background: The impact of high exercise loads on a previously healthy heart remains controversial. We examined the consequences of decades of strenuous endurance exercise at the highest competition level on heart dimensions and volumes as well as on serum biomarkers of cardiac fibrosis/remodeling. Methods and results: We compared echocardiographic measurements and serum biomarkers of cardiac fibrosis/remodeling [troponin I, galectin-3, matrix metallopeptidase-2 and -9, N-terminal pro-brain natriuretic peptide, carboxy-terminal propeptide of type I procollagen, and soluble suppressor of tumorigenicity-2 (sST-2)/interleukin(IL)-1R4] in 53 male athletes [11 former professional ('elite') and 42…

MaleCardiac fibrosis030204 cardiovascular system & hematology0302 clinical medicineReference ValuesTroponin INatriuretic peptideVentricular FunctionAtletismo - Aspectos fisiológicosBody surface areaVentricular RemodelingCorazónmedicine.diagnostic_testbiologyOrgan SizeMiddle AgedEndurance exercisePathophysiologyEchocardiographyHeart Function TestsCardiologyCardiology and Cardiovascular MedicineSportsAdultmedicine.medical_specialtymedicine.drug_classHeart VentriclesMagnetic Resonance Imaging CineTime03 medical and health sciencesCardiac magnetic resonance imagingEndurance trainingAtletaInternal medicinemedicineHumansExerciseCardiac remodelingSistema cardiovascularCardiac fibrosisbusiness.industryAthletes030229 sport sciencesmedicine.diseasebiology.organism_classificationEndocrinologyAthletesPhysical FitnessPhysical EndurancebusinessInternational Journal of Cardiology
researchProduct

Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure

2012

Aims: The purpose of this study was to evaluate the effect of transient local myocardial gene transfer of iNOS on cardiac function in a large mammal animal model of heart failure induced by chronic ischemia. Methods: Chronic myocardial ischemia was induced using a minimally invasive model in 16 landrace pigs. Upon demonstration of heart failure, eight animals were treated with liposome-mediated iNOS-gene-transfer by local intramyocardial injection; eight animals received a sham procedure to serve as control. Results: The transmurality of late enhancement (control: 46.4%, iNOS: 35.9%; p < 0.05) was significantly decreased in the ischemic area in the iNOS-treated group. Wall thickness at end-…

MaleCardiac function curvemedicine.medical_specialtyTiclopidineSwinePhysiologySus scrofaMyocardial IschemiaIschemiaContrast MediaNitric Oxide Synthase Type IIGadoliniumCoronary AngiographyContractilityRandom AllocationVentricular Dysfunction LeftGenes ReporterFibrosisPhysiology (medical)Internal medicineGenes SyntheticmedicineAnimalsTiclopidineHeart FailureDrug CarriersAspirinAspirinmedicine.diagnostic_testbusiness.industryCoronary StenosisAnticoagulantsMagnetic resonance imagingGenetic TherapyHematologymedicine.diseaseFibrosisMagnetic Resonance ImagingMyocardial ContractionClopidogrelDisease Models AnimalHeart failureLiposomesCardiologyFemaleStentsCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype…

2017

Over the last 5 years, therapies for hepatitis C virus (HCV) infection have improved significantly, achieving sustained virologic response (SVR) rates of up to 100% in clinical trials in patients with HCV genotype 1. We investigated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir +/- dasabuvir in an early access programme. This was a retrospective, multicentre, national study that included 291 treatment-naive and treatment-experienced patients with genotype 1 or 4 HCV infection. Most patients (65.3%) were male, and the mean age was 57.5years. The mean baseline viral load was 6.1 log, 69.8% had HCV 1b genotype, 72.9% had cirrhosis and 34.7% were treatment-naive. SVR at 12 w…

MaleCirrhosisSustained Virologic ResponseHepacivirusmedicine.disease_causechemistry.chemical_compound0302 clinical medicinesevere fibrosisdasabuvirMedicineAged 80 and overMiddle AgedInfectious DiseasesTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleViral loadmedicine.drugAdultmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsGenotypeHepatitis C viruscompassionate useAntiviral Agents03 medical and health sciencesVirologyInternal medicineHumansAdverse effectAgedRetrospective StudiesHepatologybusiness.industryRibavirinparitaprevirHepatitis C Chronicmedicine.diseaseVirologydigestive system diseasesOmbitasvirDiscontinuationombitasvirchemistryParitaprevirSpainhepatitis Cbusiness
researchProduct

Unexplained chronic liver disease in Ethiopia: a cross-sectional study

2018

Background Hepatitis B virus (HBV) infection is assumed to be the major cause of chronic liver disease (CLD) in sub-Saharan Africa. The contribution of other aetiological causes of CLD is less well documented and hence opportunities to modulate other potential risk factors are being lost. The aims of this study were to explore the aetiological spectrum of CLD in eastern Ethiopia and to identify plausible underlying risk factors for its development. Methods A cross-sectional study was undertaken between April 2015 and April 2016 in two public hospitals in Harar, eastern Ethiopia. The study population comprised of consenting adults with clinical and radiological evidence of chronic liver dise…

MaleCross-sectional studyEpidemiologyBiopsyChronic liver disease0302 clinical medicineRisk FactorsKhatEpidemiologyPrevalenceSIMPLE NONINVASIVE INDEX030212 general & internal medicineViral hepatitisPOPULATIONbiologymedicine.diagnostic_testSub-Saharan AfricaLiver DiseasesGastroenterologyCHRONIC HEPATITISGeneral MedicineAlcoholismLiverLiver biopsyPopulation studyFemale030211 gastroenterology & hepatologyC HEPATITISViral hepatitisLife Sciences & BiomedicineResearch ArticleAdultmedicine.medical_specialtySubstance-Related DisordersAcute Lung InjuryKHAT LEAVESAUTOIMMUNEVERBAL AUTOPSY METHODCathaVIRUS-INFECTIONCatha edulis03 medical and health sciencesInternal medicinemedicineHumanslcsh:RC799-869Science & TechnologyGastroenterology & HepatologySIGNIFICANT FIBROSISbusiness.industryHepatotoxicity1103 Clinical SciencesHepatologybiology.organism_classificationmedicine.diseaseCross-Sectional StudiesChronic Diseaselcsh:Diseases of the digestive system. GastroenterologyEthiopiabusiness
researchProduct

[Gadolinium-containing contrast agents: Gadoterat-meglumine is safe in patients with chronic renal failure].

2014

Objective To prospectively compare the renal safety of meglumine gadoterate (Gd-DOTA)-enhanced magnetic resonance imaging (MRI) to a control group (unenhanced MRI) in high-risk patients. Methods Patients with chronic kidney disease (CKD) scheduled for MRI procedures were screened. The primary endpoint was the percentage of patients with an elevation of serum creatinine levels, measured 72 ± 24 h after the MRI procedure, by at least 25 % or 44.2 μmol/l (0.5 mg/dl) from baseline. A non-inferiority margin of the between-group difference was set at −15 % for statistical analysis of the primary endpoint. Main secondary endpoints were the variation in serum creatinine and eGFR values between base…

MaleDrug-Related Side Effects and Adverse ReactionsContrast MediaAcute Kidney InjuryMeglumine gadoterateMagnetic Resonance ImagingNephrogenic Fibrosing DermopathyHeterocyclic CompoundsGd-DOTANephrogenic systemic fibrosisOrganometallic CompoundsHumansFemaleRenal Insufficiency ChronicGadolinium-based contrast agent-induced nephropathyMRIRoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
researchProduct

Presence of calreticulin mutations in JAK2-negative polycythemia vera

2014

Abstract Calreticulin (CALR) mutations have recently been reported in JAK2- and MPL-negative Myeloproliferative Neoplasms (MPN), particularly essential thrombocythemia (ET) and primary myelofibrosis (PMF).The clinical course of sporadic CALR-mutated patients seems to be more indolent than that of JAK2-mutated patients. In contrast, no CALR mutation has been found in the 647 published cases of Polycythemia Vera (PV) patients tested. Consequently, CALR mutations were considered exclusive to JAK2 and MPL mutations. Since 98% of PV patients harbor a JAK2 mutation (mostly the V617F mutation in exon 14 and more rarely, in exon 12), the absence of CALR mutations in PV seemed logical. Here, we desc…

MaleErythrocytesMESH: Thrombocytosismedicine.disease_causeMESH: Polycythemia VeraBiochemistryMESH: Janus Kinase 2MESH: GenotypeHemoglobinsMESH: Aged 80 and overPolycythemia verahemic and lymphatic diseasesPolycythemia VeraMESH: HeterozygoteAged 80 and overThrombocytosisMESH: AgedMutation[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyJanus kinase 2biologyMESH: ErythrocytesExonsHematologyLeukemiaMESH: HemoglobinsMESH: Primary MyelofibrosisThrombocythemia EssentialHeterozygoteMESH: MutationGenotypeMESH: CalreticulinImmunologyContext (language use)medicineHumansMyelofibrosisAllelesAgedMESH: HumansEssential thrombocythemiabusiness.industryMESH: AllelesCell BiologyJanus Kinase 2medicine.diseaseMESH: MalePrimary MyelofibrosisMESH: Gene DeletionMutationImmunologybiology.proteinCancer researchMESH: Thrombocythemia EssentialCalreticulinMESH: ExonsbusinessCalreticulinGene Deletion[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBlood
researchProduct